Print

Active Biotech AB Interim Report January - September 2013

2013-11-07

Laquinimod

  • Analysis of data from the Phase III ALLEGRO study shows that laquinimod provides a beneficial impact on brain tissue damage; Laquinimod-treated patients accumulated significantly less brain tissue damage caused by neurodegeneration
  • New data presented at ECTRIMS shows that laquinimod has an effect on both inflammation and the underlying mechanisms associated with disease progression in multiple sclerosis
  • Teva is planning to commence clinical trials in Huntington's disease and primary progressive multiple sclerosis (PPMS)
  • Teva will initiate a further clinical trial in multiple sclerosis (LIBRETTO)

Tasquinimod

  • Phase III 10TASQ10 study is proceeding as planned; the primary analysis of progression-free survival (PFS) and survival (OS) is expected in 2014
  • Active Biotech received a milestone payment of EUR 12 M from Ipsen

ANYARA

  • Detailed analysis provides further support for ANYARA's efficacy in a biomarker-defined sub-group of renal cell cancer patients; the result from the Phase II/III study was presented at the 2013 European Cancer Congress

Paquinimod (57-57)

  • Evaluation under way of clinical trial in systemic sclerosis

ISI

  • Project proceeding according to plan


Financial summary

SEK M Q3 Jan - Sept Jan - Dec
2013 2012 2013 2012 2012
Net sales 107.0 39.8 111.9 136.4 227.9
Operating loss 27.9 -48.2 -128.6 -168.7 -163.2
Profit/Loss after tax 29.2 -51.6 -130.0 -175.1 -175.0
Profit/loss per share 0.39 -0.75 -1.77 -2.54 -2.54

For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46-19 20 95

Hans Kolam, CFO
Tel: +46 (0)46-19 20 44

Active Biotech AB(Corp. Reg. No. 556223-9227)
Box 724, 220 07 Lund
Tel: +46 (0)46-19 20 00
Fax +46 (0)46-19 11 00

The report is also available at www.activebiotech.com


pdfActive Biotech AB Interim Report January – September 2013



Back